Sen. Charles Grassley's hall of shame: The chairman of the Senate Finance Committee, who's been trying to rally support for a bill requiring drug and device makers to disclose anything of value
> After waiting for nearly a month, officials at the National Institutes of Health alerted some 2,500 people that their names, addresses and detailed personal health information gathered from
> Drug-patent cases are clogging Canadian courts, with some 30 judges assigned to 350 cases that involve highly specialized, technical knowledge.
It's a head-to-head matchup. The National Institutes of Health has launched an 8,000-patient trial pitting GlaxoSmithKline's Tykerb against Genentech's Herceptin in aggressive breast cancer.
Gentlemen (and ladies), start your eye injections. In other Avastin news, the big trial pitting the cancer drug against Genentech sister med Lucentis is now underway. Sponsored by the National
The Lucentis versus Avastin match has moved to Canada. Officials there are arguing
The U.S. Senate wants to know why Medicare should have to spend millions on Genentech's eye drug Lucentis when the company's Avastin
Big kudos to the Novartis osteoporosis drug Reclast: A New England Journal of Medicine study showed that patients with broken hips were more likely to survive if they were given a yearly dose of the
Whoever said there's no such thing as bad publicity never worked in pharma. The latest proof of bad news-related suffering: A new report on antipsychotic drugs finds Janssen's Risperdal and
New asthma treatment guidelines could be good news for drug companies. The government advises better day-to-day control of the disease--and that probably means more widespread use of inhaled